93 results
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
24 Apr 24
Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
4:05pm
Highlights
Research and development expenses were $24.1 million for the three months ended March 31, 2024, compared to $11.0 million for the same … for the three months ended March 31, 2024, was primarily due to the increase in research and development expenses and general and administrative expenses
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
26 Mar 24
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
7:08am
in clinical trials. Viking's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve
8-K
EX-99.1
VKTX
Viking Therapeutics Inc
4 Mar 24
Other Events
4:52pm
to use the net proceeds from the offering for continued development of its VK2809, VK2735 and VK0214 programs and for general research and development … in clinical trials. Viking’s research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve
424B5
02c58m0ypt59lf3
1 Mar 24
Prospectus supplement for primary offering
4:13pm
8-K
EX-99.1
jhvfzr c37hxrdyoi
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
8-K
syoz4s869j
1 Mar 24
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
4:05pm
424B5
ajmy43e4ufo4a
27 Feb 24
Prospectus supplement for primary offering
5:21pm
8-K
EX-99.1
sjr3y
27 Feb 24
Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity
7:04am
8-K
EX-99.1
y7qhwv3yap0qt2jt3a
7 Feb 24
Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
4:09pm
8-K
EX-99.1
67zom3im
25 Oct 23
Viking Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
4:24pm
S-3ASR
m5ryxuxir72svl
26 Jul 23
Automatic shelf registration
5:26pm
8-K
EX-99.1
8itjs
26 Jul 23
Viking Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
4:23pm
8-K
EX-99.1
ezkpr9
26 Apr 23
Viking Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
4:06pm